Abstract
The combination of a beta blocker and a vasodilator is logical in the treatment of high blood pressure. Systemic arteriolar dilatation is beneficial to reduce the elevated peripheral resistance and hence to decrease cardiac afterload. β-Adrenoceptor blockade exerts its own antihypertensive activity and also suppresses the reflex tachycardia induced by vasodilatation. The combined β- and α-adrenoceptor blockade exerted by carvedilol imposes these beneficial hemodynamic effects. Carvedilol is a nonselective β-adrenoceptor antagonist, devoid of intrinsic sympathomimetic activity and possessing selective α<inf>1</inf> adrenoceptor-blocking activity, although this is considerably weaker than its β-adrenoceptor antagonistic activity. One isomer [S (-)-carvedilol] contains both the β-and α-adrenoceptor activity, whereas R(+)-carvedilol is only a weak alpha blocker. Carvedilol is produced as the racemate. The hemodynamic profile is in accordance with that to be expected from the combination of beta and alpha blockade. © 1993 S. Karger AG, Basel.
| Original language | English |
|---|---|
| Pages (from-to) | 19-23 |
| Journal | Cardiology |
| Volume | 82 |
| DOIs | |
| Publication status | Published - 1993 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Pharmacodynamic profile of carvedilol'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver